Skip to search formSkip to main contentSkip to account menu

figitumumab

A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CP 751871

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC.
8091 Background: Signaling of Insulin like Growth Factors (IGFs) through the IGF type 1 receptor (IGF-IR) induces tumor… 
Review
2016
Review
2016
Emerging antibodies for the treatment of multiple myeloma
ABSTRACT Introduction: Monoclonal antibodies mark the beginning of a new era in the context of multiple myeloma (MM) treatment… 
2016
2016
Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871).
3539 Background: Free IGF-1 (fIGF-1) represents the biologically active fraction of IGF-1, the main circulating ligand of the… 
Review
2011
Review
2011
Targeting the insulin growth factor pathway in gastrointestinal cancers.
Insulin-like growth factor 1 (IGF-1)-directed therapy is currently at a crossroads. After decades of research, several agents… 
2011
2011
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?
The selective targeting of oncogenic proteins and its translation into disease-specific clinical trials have largely driven the… 
2011
2011
The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status
Purpose: Insulin-like growth factor (IGF)-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of… 
2011
2011
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).
3525 Background: Figitumumab (F; CP-751,871) is a fully human monoclonal antibody (mAb) that inhibits IGF-IR. This phase II trial… 
2010
2010
Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies
Activation of the insulin-like growth factor (IGF) pathway, by binding of the growth factors IGF-I and IGF-II to the receptors… 
2010
2010
Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys.
BACKGROUND Insulin-like growth factor (IGF) signaling has been linked to tumor cell survival and tumorigenesis. The anti-IGF-1… 
2010
2010
A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).
4662 Background: F is a fully human IgG2 monoclonal antibody against insulin- like growth factor-1 receptor (IGF1R). Activation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)